1180 related articles for article (PubMed ID: 33283989)
1. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
[TBL] [Abstract][Full Text] [Related]
2. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Locatelli F; Lang P; Wall D; Meisel R; Corbacioglu S; Li AM; de la Fuente J; Shah AJ; Carpenter B; Kwiatkowski JL; Mapara M; Liem RI; Cappellini MD; Algeri M; Kattamis A; Sheth S; Grupp S; Handgretinger R; Kohli P; Shi D; Ross L; Bobruff Y; Simard C; Zhang L; Morrow PK; Hobbs WE; Frangoul H;
N Engl J Med; 2024 May; 390(18):1663-1676. PubMed ID: 38657265
[TBL] [Abstract][Full Text] [Related]
3. Highly efficient therapeutic gene editing of human hematopoietic stem cells.
Wu Y; Zeng J; Roscoe BP; Liu P; Yao Q; Lazzarotto CR; Clement K; Cole MA; Luk K; Baricordi C; Shen AH; Ren C; Esrick EB; Manis JP; Dorfman DM; Williams DA; Biffi A; Brugnara C; Biasco L; Brendel C; Pinello L; Tsai SQ; Wolfe SA; Bauer DE
Nat Med; 2019 May; 25(5):776-783. PubMed ID: 30911135
[TBL] [Abstract][Full Text] [Related]
4. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
5. Exagamglogene Autotemcel for Severe Sickle Cell Disease.
Frangoul H; Locatelli F; Sharma A; Bhatia M; Mapara M; Molinari L; Wall D; Liem RI; Telfer P; Shah AJ; Cavazzana M; Corbacioglu S; Rondelli D; Meisel R; Dedeken L; Lobitz S; de Montalembert M; Steinberg MH; Walters MC; Eckrich MJ; Imren S; Bower L; Simard C; Zhou W; Xuan F; Morrow PK; Hobbs WE; Grupp SA;
N Engl J Med; 2024 May; 390(18):1649-1662. PubMed ID: 38661449
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 Editing of the
Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL
N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679
[TBL] [Abstract][Full Text] [Related]
7. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
[TBL] [Abstract][Full Text] [Related]
8. The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment.
Mahmoud Ahmed NH; Lai MI
Cardiovasc Hematol Disord Drug Targets; 2023; 22(4):226-236. PubMed ID: 36734897
[TBL] [Abstract][Full Text] [Related]
9. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
[TBL] [Abstract][Full Text] [Related]
10. Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach.
Eckrich MJ; Frangoul H
Semin Hematol; 2023 Jan; 60(1):3-9. PubMed ID: 37080708
[TBL] [Abstract][Full Text] [Related]
11. Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.
Weber L; Frati G; Felix T; Hardouin G; Casini A; Wollenschlaeger C; Meneghini V; Masson C; De Cian A; Chalumeau A; Mavilio F; Amendola M; Andre-Schmutz I; Cereseto A; El Nemer W; Concordet JP; Giovannangeli C; Cavazzana M; Miccio A
Sci Adv; 2020 Feb; 6(7):. PubMed ID: 32917636
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.
Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR
Gene; 2022 Apr; 820():146289. PubMed ID: 35143940
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic base editing of human hematopoietic stem cells.
Zeng J; Wu Y; Ren C; Bonanno J; Shen AH; Shea D; Gehrke JM; Clement K; Luk K; Yao Q; Kim R; Wolfe SA; Manis JP; Pinello L; Joung JK; Bauer DE
Nat Med; 2020 Apr; 26(4):535-541. PubMed ID: 32284612
[TBL] [Abstract][Full Text] [Related]
14. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
[TBL] [Abstract][Full Text] [Related]
16. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34
Lamsfus-Calle A; Daniel-Moreno A; Antony JS; Epting T; Heumos L; Baskaran P; Admard J; Casadei N; Latifi N; Siegmund DM; Kormann MSD; Handgretinger R; Mezger M
Sci Rep; 2020 Jun; 10(1):10133. PubMed ID: 32576837
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β
Fu B; Liao J; Chen S; Li W; Wang Q; Hu J; Yang F; Hsiao S; Jiang Y; Wang L; Chen F; Zhang Y; Wang X; Li D; Liu M; Wu Y
Nat Med; 2022 Aug; 28(8):1573-1580. PubMed ID: 35922667
[TBL] [Abstract][Full Text] [Related]
18. Tweaking genes with CRISPR or viruses fixes blood disorders.
Kaiser J
Science; 2020 Dec; 370(6522):1254-1255. PubMed ID: 33303593
[No Abstract] [Full Text] [Related]
19. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.
Ravi NS; Wienert B; Wyman SK; Bell HW; George A; Mahalingam G; Vu JT; Prasad K; Bandlamudi BP; Devaraju N; Rajendiran V; Syedbasha N; Pai AA; Nakamura Y; Kurita R; Narayanasamy M; Balasubramanian P; Thangavel S; Marepally S; Velayudhan SR; Srivastava A; DeWitt MA; Crossley M; Corn JE; Mohankumar KM
Elife; 2022 Feb; 11():. PubMed ID: 35147495
[TBL] [Abstract][Full Text] [Related]
20. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
Antoniani C; Meneghini V; Lattanzi A; Felix T; Romano O; Magrin E; Weber L; Pavani G; El Hoss S; Kurita R; Nakamura Y; Cradick TJ; Lundberg AS; Porteus M; Amendola M; El Nemer W; Cavazzana M; Mavilio F; Miccio A
Blood; 2018 Apr; 131(17):1960-1973. PubMed ID: 29519807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
